| Mitsubishi Chemical Medience Corporation Patent applications |
| Patent application number | Title | Published |
|---|
| 20110262958 | DEVICE FOR EXAMINING MYOCARDIAL TOXICITY, CHIP FOR EXAMINING MYOCARDIAL TOXICITY AND METHOD FOR EXAMINING MYOCARDIAL TOXICITY - [Problem] To provide a device and a method for examining myocardial toxicity, which can be realized in vitro in an equivalent manner as those conventionally carried out in vivo. | 10-27-2011 |
| 20110189704 | NON-SPECIFIC REACTION INHIBITOR - Disclosed is a non-specific reaction inhibitor for use in an immunological measurement, comprising a complex of an antibody or a fragment of the antibody capable of specifically binding to a non-specific reaction factor, and a polymer. The non-specific reaction inhibitor can inhibit a non-specific reaction which may interfere with the accurate detection or quantification of a trace substance in an immunological measurement method. | 08-04-2011 |
| 20110143369 | METHOD FOR DETERMINING TREATMENT OF DISSEMINATED INTRAVASCULAR COAGULATION - A method for determining an appropriate treatment option for a patient who has been diagnosed with disseminated intravascular coagulation (DIC) but who may have thrombotic thrombocytopenic purpura (TTP), by analyzing the amount and/or enzyme activity of a von Willebrand factor (vWF)-cleaving protease (ADAMTS13) and the amount of vWF in a patient that has been diagnosed with DIC is disclosed. Using the method of the present invention, a differential diagnosis of patients with thrombotic thrombocytopenic purpura (TTP) can be made from among patients diagnosed with DIC, which could not previously be distinguished on the basis of only clinical findings or known markers. Also disclosed is a kit for determining an appropriate treatment option, the kit comprising an antibody or a fragment thereof which specifically binds to ADAMTS13. | 06-16-2011 |
| 20110039721 | METHOD FOR PREDICTION ABOUT CARCINOGENICITY OF SUBSTANCE IN RODENT - Disclosed is a method for predicting about the carcinogenicity of a substance of interest in a rodent, which comprises the steps of: administering a solution of the substance to a test group and administering a solvent used in the solution to a control group; extracting mRNA from each of the test group and the control group, and measuring the expression level of mRNA for each of genes obtained by selecting at least one gene from (A) genes each comprising a nucleotide sequence depicted in any one of SEQ ID NOs: 1 to 5, (B) genes each comprising a nucleotide sequence depicted in any one of SEQ ID NOs: 6 to 8 and (C) genes each comprising a nucleotide sequence depicted in any one of SEQ ID NOs: 9 to 32; determining whether or not a significant difference in the level of mRNA expressed from the gene is observed between the test group and the control group; and determining that the substance has carcinogenicity when a significant difference in the level of the expression of mRNA from any one of the genes is observed between the test group and the control group and the direction of increase or decrease in the level of the expression of mRNA from any one of the genes is the same as the tendency which is previously defined for each gene. | 02-17-2011 |
| 20110014633 | ELECTRIC ANALYSIS METHOD - Disclosed is an analysis method comprising the steps of: | 01-20-2011 |
| 20100178692 | MODEL CELL CHIP, APPARATUS FOR EVALUATING DRUG EFFECT USING THE MODEL CELL CHIP AND METHOD OF EVALUATING DRUG EFFECT - The present invention provides an apparatus for evaluating a drug effect enabling on-chip evaluation of the effect of a drug while the drug is acting on hERG-expressing cells. The present invention also provides a myocardial toxicity test apparatus and method therefor enabling in vitro myocardial toxicity testing that has previously been performed in vivo. | 07-15-2010 |
| 20100173351 | CARDIAC REENTRY MODEL CHIP AND APPARATUS AND METHOD FOR EVALUATING DRUG USING THE CARDIAC REENTRY MODEL CHIP - A chip has been developed that can accurately measure cell potential and cell morphology on a single cell basis. The chip also constitutes a cardiac model that comprises a closed loop whereupon cardiomyocytes and fibroblasts are suitably dispersed and arranged, and that can evaluate the effects of a drug thereon. An in vitro cardiac reentry model chip is fabricated by constructing a closed loop comprising cardiomyocytes and fibroblasts arrayed on transparent electrodes formed on a transparent substrate by using a constitution where single cells are enclosed in a specific spatial configuration. A pulse wave of a random cardiomyocyte or a specific cardiomyocyte is propagated on both sides of the loop, and the pulsation status of the cells in the loop is detected electrically. A drug is applied to this cardiac reentry model chip, and the benefit or toxicity of the drug to cardiomyocytes is evaluated by measuring the cell potentials of individual cells. | 07-08-2010 |
